Drugs / Alpha-galactosidase A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00048906 | Nov 2002 → Nov 2003 | Fabry disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alpha-galactosidase A | “Replagal is a genetically engineered form of Alpha-galactosidase A.” NCT00048906 ↗ |
| Known as | Replagal | “Replagal is a genetically engineered form of Alpha-galactosidase A.” NCT00048906 ↗ |
| Modality | Protein / enzyme biologic | “Replagal is a genetically engineered form of Alpha-galactosidase A.” NCT00048906 ↗ |
| Route | Intravenous | “intravenous (IV) infusions of Replagal” NCT00048906 ↗ |